A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Winter depression can take a toll on your mind and body. Local health experts say depression is something you should take ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has underperformed its large-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Even though JNJ has displayed an improving track record of beating ...

The Detroit Lions and offensive coordinator Ben Johnson are in quite the unique position this weekend. Detroit's talented play-caller is one of the most coveted coaching candidates in the NFL.

Johnson & Johnson (NYSE ... point happened after the late 2021 approval for the treatment of bipolar depression. Caplyta is on track to generate nearly $700 million in net sales in 2024 and ...

Johnson & Johnson will pay Intra-Cellular shareholders ... which treats schizophrenia and bipolar I and II depression. The company also has other drugs in the pipeline to treat Alzheimer's Disease ...

The deal would add to J & J’s portfolio lumateperone, an Intra-Cellular drug branded Caplyta, a pill that treats bipolar depression and schizophrenia. Analysts predict the drug’s sales could ...